Trial Outcomes & Findings for Low-Level Laser in Head and Neck Chronic Lymphedema (NCT NCT04482855)

NCT ID: NCT04482855

Last Updated: 2024-11-19

Results Overview

Head and Neck Lymphedema and Fibrosis Assessment Criteria Change in total severity of external LEF from baseline to 8-week post-intervention visits. A larger change in this score means more reduction in the severity of external LEF. External LEF is measured by HN-LEF Assessment Criteria. The total external LEF severity score is calculated by summing the severity score of each site (total 9 sites, severity score ranging from 0-27). For each site, the severity of LEF includes no LEF (=0), mild (=1), moderate (=2), and severe (=3).

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

25 participants

Primary outcome timeframe

Baseline, 8-week post-intervention visit

Results posted on

2024-11-19

Participant Flow

Participant milestones

Participant milestones
Measure
Group 1 (Laser Group)
Group 1 (laser group): After completion of the baseline measurements, Group 1 participants will be scheduled for LLLT. After completion of LLLT, participants will be scheduled for the 4-week and 8-week follow up data collection. Low-level laser: Low-level laser therapy
Group 2 (Wait-list Control Group)
Group 2 (wait-list control group): Group 2 participants will not undergo LLLT therapy but will complete all the same study assessments as the laser therapy group, including the baseline, and follow-up assessments. After the 8-week follow-up assessment, participants will be offered the same LLLT as the laser group.
Overall Study
STARTED
12
13
Overall Study
COMPLETED
9
13
Overall Study
NOT COMPLETED
3
0

Reasons for withdrawal

Reasons for withdrawal
Measure
Group 1 (Laser Group)
Group 1 (laser group): After completion of the baseline measurements, Group 1 participants will be scheduled for LLLT. After completion of LLLT, participants will be scheduled for the 4-week and 8-week follow up data collection. Low-level laser: Low-level laser therapy
Group 2 (Wait-list Control Group)
Group 2 (wait-list control group): Group 2 participants will not undergo LLLT therapy but will complete all the same study assessments as the laser therapy group, including the baseline, and follow-up assessments. After the 8-week follow-up assessment, participants will be offered the same LLLT as the laser group.
Overall Study
Lost to Follow-up
1
0
Overall Study
Withdrew from the study before attending the study intervention sessions due to unexpected job duty
1
0
Overall Study
Withdrew from the study before attending the study intervention sessions due to new cancer diagnosis
1
0

Baseline Characteristics

Low-Level Laser in Head and Neck Chronic Lymphedema

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Group 1 (Laser Group)
n=12 Participants
Group 1 (laser group): After completion of the baseline measurements, Group 1 participants will be scheduled for LLLT. After completion of LLLT, participants will be scheduled for the 4-week and 8-week follow up data collection. Low-level laser: Low-level laser therapy
Group 2 (Wait-list Control Group)
n=13 Participants
Group 2 (wait-list control group): Group 2 participants will not undergo LLLT therapy but will complete all the same study assessments as the laser therapy group, including the baseline, and follow-up assessments. After the 8-week follow-up assessment, participants will be offered the same LLLT as the laser group.
Total
n=25 Participants
Total of all reporting groups
Age, Continuous
59.5 years
STANDARD_DEVIATION 5.06 • n=99 Participants
62.3 years
STANDARD_DEVIATION 6.01 • n=107 Participants
61.0 years
STANDARD_DEVIATION 5.65 • n=206 Participants
Sex: Female, Male
Female
2 Participants
n=99 Participants
1 Participants
n=107 Participants
3 Participants
n=206 Participants
Sex: Female, Male
Male
10 Participants
n=99 Participants
12 Participants
n=107 Participants
22 Participants
n=206 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Asian
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=99 Participants
1 Participants
n=107 Participants
1 Participants
n=206 Participants
Race (NIH/OMB)
White
12 Participants
n=99 Participants
12 Participants
n=107 Participants
24 Participants
n=206 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Region of Enrollment
United States
12 participants
n=99 Participants
13 participants
n=107 Participants
25 participants
n=206 Participants

PRIMARY outcome

Timeframe: Baseline, 8-week post-intervention visit

Head and Neck Lymphedema and Fibrosis Assessment Criteria Change in total severity of external LEF from baseline to 8-week post-intervention visits. A larger change in this score means more reduction in the severity of external LEF. External LEF is measured by HN-LEF Assessment Criteria. The total external LEF severity score is calculated by summing the severity score of each site (total 9 sites, severity score ranging from 0-27). For each site, the severity of LEF includes no LEF (=0), mild (=1), moderate (=2), and severe (=3).

Outcome measures

Outcome measures
Measure
Group 1 (Laser Group)
n=12 Participants
Group 1 (laser group): After completion of the baseline measurements, Group 1 participants will be scheduled for LLLT. After completion of LLLT, participants will be scheduled for the 4-week and 8-week follow up data collection. Low-level laser: Low-level laser therapy
Group 2 (Wait-list Control Group)
n=13 Participants
Group 2 (wait-list control group): Group 2 participants will not undergo LLLT therapy but will complete all the same study assessments as the laser therapy group, including the baseline, and follow-up assessments. After the 8-week follow-up assessment, participants will be offered the same LLLT as the laser group.
Total Severity of External Lymphedema and Fibrosis (LEF)
Total severity score of LEF at baseline visit
5.42 score on a scale
Standard Deviation 2.07
4.08 score on a scale
Standard Deviation 2.33
Total Severity of External Lymphedema and Fibrosis (LEF)
Total severity score of LEF at 8-week post-intervention visit
3.22 score on a scale
Standard Deviation 1.86
4.62 score on a scale
Standard Deviation 1.71

SECONDARY outcome

Timeframe: Baseline, 8-week post-intervention visit

Head and Neck Lymphedema and Fibrosis Symptom Inventory Change in symptom burden score from baseline to 8-week post-intervention. A larger change in this score means decreased symptom burden. Symptom burden is assessed by Head and Neck Lymphedema and Fibrosis Symptom Inventory (HN-LEF SI). Higher scores (score ranging from 0-5) indicate increased symptom burden. There are 7 subscales and only one subscale (Soft Tissues and Neurologic Toxicity) score is reported here.

Outcome measures

Outcome measures
Measure
Group 1 (Laser Group)
n=12 Participants
Group 1 (laser group): After completion of the baseline measurements, Group 1 participants will be scheduled for LLLT. After completion of LLLT, participants will be scheduled for the 4-week and 8-week follow up data collection. Low-level laser: Low-level laser therapy
Group 2 (Wait-list Control Group)
n=13 Participants
Group 2 (wait-list control group): Group 2 participants will not undergo LLLT therapy but will complete all the same study assessments as the laser therapy group, including the baseline, and follow-up assessments. After the 8-week follow-up assessment, participants will be offered the same LLLT as the laser group.
Symptom Burden Score: Soft Tissues and Neurologic Toxicity Subscale
Soft Tissues and Neurologic Toxicity at baseline
2.46 score on a scale
Standard Deviation 0.97
1.63 score on a scale
Standard Deviation 1.03
Symptom Burden Score: Soft Tissues and Neurologic Toxicity Subscale
Soft Tissues and Neurologic Toxicity at 8-week post-intervention visit
1.73 score on a scale
Standard Deviation 1.32
1.23 score on a scale
Standard Deviation 0.92

SECONDARY outcome

Timeframe: Baseline, 8-week post-intervention visit

Change in neck range of motion degree from baseline to 8-week post-intervention. A larger change in this degree means better outcome with increased neck range of motion. Cervical Range of Motion Device, a valid and reliable tool, was used to measure the amount of neck movement (degrees) for the following neck movements: forward flexion, extension, right and left lateral flexion, and right and left rotation. Only right lateral rotation is reported here.

Outcome measures

Outcome measures
Measure
Group 1 (Laser Group)
n=12 Participants
Group 1 (laser group): After completion of the baseline measurements, Group 1 participants will be scheduled for LLLT. After completion of LLLT, participants will be scheduled for the 4-week and 8-week follow up data collection. Low-level laser: Low-level laser therapy
Group 2 (Wait-list Control Group)
n=13 Participants
Group 2 (wait-list control group): Group 2 participants will not undergo LLLT therapy but will complete all the same study assessments as the laser therapy group, including the baseline, and follow-up assessments. After the 8-week follow-up assessment, participants will be offered the same LLLT as the laser group.
Neck Range of Motion Degree: Right Lateral Rotation
Right lateral rotation at baseline visit
45.38 degrees of neck movements
Standard Deviation 13.54
48.04 degrees of neck movements
Standard Deviation 6.98
Neck Range of Motion Degree: Right Lateral Rotation
Right lateral rotation at 8-week post-intervention visit
52.78 degrees of neck movements
Standard Deviation 11.18
47.85 degrees of neck movements
Standard Deviation 10.92

SECONDARY outcome

Timeframe: Baseline, 8-week post-intervention visit

EORTC QLQ-H\&N35 was used to assess HNC-related quality of life. Change in EORTC QLQ-H\&N35 score from baseline to 8-week post-intervention. A larger reduction in this score means decreased symptom burden and better quality of life. The HNC-specific EORTC QLQ-H\&N35 module is a supplement, containing seven multi-item scales (pain, swallowing, senses problems, speech problems, trouble with social eating and social contact, and less sexuality) and eleven single-item scales (teeth, opening mouth, dry mouth, sticky saliva, coughing, felt ill, pain killers, nutritional supplements, feeding tube, weight loss, weight gain). The QLQ-H\&N35 scale employs a 4-point response format (''not at all" to ''very much"). Scale scores are transformed to a scale from 0 to 100 according to the EORTC scoring algorithm. For the symptoms scales, a higher score indicates a higher level of symptom burden. Only feeding tube scale is reported here.

Outcome measures

Outcome measures
Measure
Group 1 (Laser Group)
n=12 Participants
Group 1 (laser group): After completion of the baseline measurements, Group 1 participants will be scheduled for LLLT. After completion of LLLT, participants will be scheduled for the 4-week and 8-week follow up data collection. Low-level laser: Low-level laser therapy
Group 2 (Wait-list Control Group)
n=13 Participants
Group 2 (wait-list control group): Group 2 participants will not undergo LLLT therapy but will complete all the same study assessments as the laser therapy group, including the baseline, and follow-up assessments. After the 8-week follow-up assessment, participants will be offered the same LLLT as the laser group.
Quality of Life Score: Feeding Tube
Quality of life -feeding tube scale score at baseline visit
16.67 score on a scale
Standard Deviation 38.92
15.38 score on a scale
Standard Deviation 37.55
Quality of Life Score: Feeding Tube
Quality of life -feeding tube scale score at 8-week post-intervention visit
0 score on a scale
Standard Deviation 0
7.69 score on a scale
Standard Deviation 27.74

Adverse Events

Group 1 (Laser Group)

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Group 2 (Wait-list Control Group)

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Jie Deng

University of Pennsylvania School of Nursing

Phone: 2155734729

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place